Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1204
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 325–336 of 1,204 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596
Site status not listed — check the official record
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Interventions
Obinutuzumab, Glofitamab
Drug
Lead sponsor
Reid Merryman, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076
Status at this site: Recruiting
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
150
States / cities
Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517
Status at this site: Recruiting
View directory record Official record
Conditions
Hemolytic Disease of the Fetus and Newborn
Interventions
Nipocalimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920
Status at this site: Recruiting
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343, JNJ-95298177, JNJ-87189401
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GBPDC: Gut-Brain in PD Consortium Master Protocol

NCT07567794
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Parkinson Disease (PD), PARKINSON DISEASE (Disorder), Gut Microbiome, Gut Microbiota, Prodromal Parkinsons Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
21 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

NCT05610163
Site status not listed — check the official record
View directory record Official record
Conditions
Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
679
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional

Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease

NCT07843004
Status at this site: Recruiting
View directory record Official record
Conditions
Structural Heart Abnormality, Valve Heart Disease, Heart Diseases, Cardiovascular Diseases
Interventions
EHR Alert
Device
Lead sponsor
Pierre Elias
Other
Eligibility
40 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT03564340
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions
Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Myeloid Leukemia, Philadelphia Positive
Interventions
Asciminib Pediatric formulation group, Asciminib Adult formulation group
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 3 Interventional

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990
Status at this site: Recruiting
View directory record Official record
Conditions
Optic Neuritis, Myelitis, Myelitis, Transverse
Interventions
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:06 AM EDT
Recruiting Phase 1 Interventional

Post-Vasectomy Pain Study

NCT07824258
Status at this site: Recruiting
View directory record Official record
Conditions
Vasectomy, NSAIDs, Post-operative Care
Interventions
Acetaminophen, ibuprofen, oxycodone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 4:06 AM EDT

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.